Among patients with low-grade, intermediate-risk NMIBC, UGN-102 generated robust, durable responses in an analysis of the ...

Using the Decipher Bladder test to determine each tumor’s molecular subtype, researchers found that NMIBC patients with ...

Among patients with suspected MIBC, the incorporation of mpMRI for initial staging prior to transurethral resection of ...

Background Bladder neck transection ... have undergone previous transurethral resection of the prostate (TUR-P), and in those with large median lobes or prostate cancer protruding into the bladder ...

Neoadjuvant chemoimmunotherapy for muscle-invasive bladder cancer (MIBC) followed by risk-adapted therapy led to high rates ...

Therefore, re-resection of the bed of a T1G3 tumor within 4–6 weeks of the initial transurethral resection of bladder tumor is essential for accurate staging. Detrusor-muscle tissue should be ...

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors ...

Pruthi et al. retrospectively assessed the records of 22 patients with superficial bladder cancer who had received conservative treatment (no transurethral resection of bladder tumor within the ...

A phase II clinical trial found that combining radiotherapy with immune checkpoint inhibitors (durvalumab and tremelimumab) ...

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...

UGN-102 led to durable responses in low-grade, intermediate-risk bladder cancer, per phase 3 study findings at the 2025 ...